Moderate EvidencePeptide

Sermorelin

GHRH (1-29)

Growth Hormone-Releasing Hormone Analog

Last updated: August 2026

Evidence Level: Moderate Evidence

Some human data, strong animal studies, plausible mechanism

Regulatory Status: Previously FDA-approved as Geref, withdrawn from the market in 2008 for commercial reasons. The FDA later determined it was not withdrawn for safety or effectiveness. All sermorelin today is compounded, not an approved finished product.

Sermorelin is the first 29 amino acids of your own growth hormone-releasing hormone, the shortest piece that still works. It prompts the pituitary to release growth hormone in natural pulses. It was FDA-approved as Geref for growth hormone deficiency in children, and its manufacturer discontinued it in 2008 for business reasons rather than safety problems.

How It Works

Your hypothalamus makes a 44-amino-acid hormone called GHRH that tells the pituitary to release growth hormone. Researchers found that only the first 29 amino acids are needed for that signal to work. Sermorelin is exactly that fragment.

What that buys you. Because sermorelin acts on the pituitary rather than replacing growth hormone directly, your body keeps control of the release. GH comes out in pulses, mostly during early deep sleep, and the normal negative-feedback loop stays intact. If GH and IGF-1 get high enough, somatostatin pushes back and release slows down. Injecting synthetic growth hormone bypasses all of that.

The practical limitation. Sermorelin has a very short half-life, roughly 10 to 20 minutes. That is why it needs frequent dosing, usually nightly, and it is the main reason longer-acting GHRH analogs like CJC-1295 and tesamorelin were developed.

It only works if your pituitary works. This is the part people miss. Sermorelin is a signal, not a replacement. If someone has genuine pituitary failure, sermorelin has nothing to act on. That is also why it was historically used as a diagnostic agent: give sermorelin, measure the GH response, and you learn whether the problem is in the pituitary or upstream of it.

Why it is not on the shelf. Sermorelin was approved as Geref, first in 1990 for diagnostic use and then in 1997 for growth hormone deficiency in children. EMD Serono discontinued it in 2008 and asked the FDA to withdraw the approvals. Recombinant human growth hormone had taken over the pediatric market, and Geref was no longer commercially worth making. The FDA later formally determined that Geref was not withdrawn for reasons of safety or effectiveness, which is a meaningful distinction: the drug worked and was safe enough, it just did not sell.

Evidence by Outcome

Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.

Evidence at a glance

How we grade

HormonalModerate
OtherVery Low

Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.

HormonalModerate certainty

Increases growth hormone release and supports growth in children with growth hormone deficiency.

Population: Children with idiopathic growth hormone deficiency and growth failure

Why this rating

This indication cleared the FDA approval bar in 1997, which requires adequate and well-controlled trials, and the agency later confirmed the product was not withdrawn for efficacy reasons. Downgraded from high because the supporting trials predate modern reporting standards and are not readily available for independent re-analysis, and because recombinant growth hormone superseded it clinically.

GRADE downgrade factors applied

Risk of bias: Methodological flaws in the studies (e.g. lack of blinding, allocation concealment, high attrition).

Supporting studies

Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn for Reasons of Safety or Effectiveness
Federal Register2013
FDA determination confirming approval history and that withdrawal was for commercial reasons.

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

OtherVery Low certainty

Improves body composition, energy, or markers of aging in healthy adults.

Population: Healthy adults without growth hormone deficiency. This is the population sermorelin is most often prescribed to today.

Why this rating

Sermorelin's approval was for growth hormone deficiency in children. We could not identify published randomized trials testing sermorelin for body composition, energy, sleep, or aging markers in healthy adults. The case rests on extrapolating from growth hormone physiology, and growth hormone therapy itself produces only modest and inconsistent body-composition changes in healthy adults. The compound is real and the mechanism is real; the specific claim is untested.

GRADE downgrade factors applied

Indirectness: Studied population, intervention, comparator, or outcome differs from the question being answered.
Imprecision: Wide confidence intervals or small sample size, the estimate could be substantially different.

Supporting studies

Geref (sermorelin acetate) approval history
FDA Orange Book1997
Approved indications were diagnostic use and pediatric growth hormone deficiency. No adult wellness indication was ever approved or, so far as we can determine, formally studied.

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

Potential Benefits

Has a genuine FDA approval history, which almost no other peptide in this category can claim
The FDA formally determined it was not withdrawn from sale for safety or effectiveness reasons
Preserves natural pulsatile GH release and normal feedback control, unlike injected growth hormone
Well-characterized safety profile from its years as an approved pediatric drug
Short half-life means that if something goes wrong, it clears quickly
Available through compounding pharmacies, so supply is more consistent than gray-market peptides

Risks & Considerations

The approved indication was growth hormone deficiency in children, not anti-aging or body composition in adults
No published trials support the adult wellness uses it is most often prescribed for today
Short half-life requires nightly injections, which is a real adherence burden
Common effects include injection site reactions, flushing, headache, and dizziness
Raising IGF-1 chronically carries theoretical concerns as a growth signal, unstudied over the long term at these doses
Every dose today is compounded, so potency and purity depend entirely on the pharmacy
Does not work if the pituitary itself is the problem

Dosing Information

The approved pediatric dosing was well defined. Adult wellness dosing is a convention established by clinics rather than by trials, and you should know which one you are being quoted.

•Historical approved pediatric dose: 0.03mg per kilogram once daily at bedtime
•Typical adult clinic protocols: 100 to 500mcg subcutaneously at bedtime
•Bedtime dosing matches the natural GH pulse during early deep sleep
•Usually taken on an empty stomach, since elevated blood sugar blunts GH release
•Frequently prescribed 5 nights on, 2 nights off, a convention rather than a trial-derived schedule
•Baseline and follow-up IGF-1 testing is the only objective way to know it is doing anything

Need to mix this from a vial?

Use our reconstitution calculator to get the exact insulin syringe units to draw.

Practical Tips

1Ask your prescriber to test IGF-1 before starting and again 6 to 8 weeks in. Without that, you are guessing
2If nightly injections are the obstacle, tesamorelin and CJC-1295 with DAC last longer, though only tesamorelin has FDA approval
3Use a 503A or 503B compounding pharmacy that will provide a certificate of analysis, not an overseas research-chemical vendor
4Give it on an empty stomach at bedtime. Eating a carbohydrate-heavy meal beforehand blunts the response
5Track the things you actually care about (sleep quality, recovery, body composition) rather than relying on how you feel about the injection
6Discuss the IGF-1 question with your doctor if you have a personal or family cancer history

Key Research

Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

Federal Register, 2013

The FDA formally determined that Geref was withdrawn from the market for commercial reasons, not because of safety or effectiveness problems. EMD Serono notified the FDA of the discontinuation in 2008.

View Study

Geref (sermorelin acetate) approval history

FDA Orange Book, 1997

Approved under NDA 19-863 in 1990 for diagnostic use and NDA 20-443 in 1997 for the treatment of idiopathic growth hormone deficiency in children with growth failure. Both now sit on the Discontinued Drug Product List.

Want to learn more?

Explore related content and talk to a healthcare provider.

Browse All Treatments Find Your Goal

Always consult a healthcare provider before starting any treatment.

Frequently Asked Questions

Is sermorelin FDA-approved?

Not currently, but it used to be. Sermorelin was approved as Geref, first in 1990 for diagnostic use and then in 1997 for growth hormone deficiency in children. EMD Serono discontinued it in 2008 and asked the FDA to withdraw the approvals. The FDA later formally determined the product was not withdrawn for safety or effectiveness reasons, which means it was a business decision. Every dose prescribed today is compounded rather than an approved finished product.

Why was sermorelin taken off the market?

Commercial reasons. Recombinant human growth hormone had taken over the pediatric growth hormone deficiency market, and Geref was no longer worth manufacturing. The FDA published a determination in 2013 confirming the withdrawal was not for reasons of safety or effectiveness. This is a meaningful distinction from drugs pulled because they harmed people.

What is the difference between sermorelin and CJC-1295?

Both are GHRH analogs that tell the pituitary to release growth hormone. The difference is duration. Sermorelin lasts roughly 10 to 20 minutes and needs nightly dosing. CJC-1295 with DAC was engineered to bind to albumin in the blood and lasts about a week. Sermorelin has an FDA approval history; CJC-1295 does not, though it has a published human pharmacology study.

Does sermorelin work for anti-aging?

There is no published trial evidence for that use. Sermorelin was approved for growth hormone deficiency in children, and we could not identify randomized trials testing it for body composition, energy, or aging markers in healthy adults. The reasoning is inferential: sermorelin raises growth hormone, and growth hormone declines with age. That is a hypothesis, and it has not been tested for this compound in this population.

How long does sermorelin take to work?

IGF-1 levels typically respond within a few weeks and can be measured with a blood test. That is the only well-documented effect. Clinics commonly quote 3 to 6 months for subjective changes in sleep, recovery, or body composition, but those timelines come from protocol convention rather than published trials.

What are the side effects of sermorelin?

The most common are injection site reactions, flushing, headache, and dizziness, which is consistent with its safety profile as an approved pediatric drug. Because it raises growth hormone and IGF-1, it can also produce the classic growth hormone effects at higher doses: fluid retention, joint aches, and reduced insulin sensitivity. Its short half-life means these clear quickly if you stop.

Is sermorelin safer than growth hormone injections?

The mechanistic argument is that it should be, because it works through your own pituitary and preserves the feedback loop that shuts release down when levels get too high. Injected growth hormone bypasses that safeguard entirely. This has not been tested head-to-head, so treat it as a well-reasoned expectation rather than a demonstrated fact.

New to Peptides?

Learn the basics of peptide therapy, how to inject safely, and what to look for in quality sources.

What Are Peptides? Peptide Safety Guide

Compare Sermorelin

Sermorelin vs Tesamorelin

Same mechanism, very different evidence

Related Peptides

CJC-1295 / IpamorelinGHRH Analog + Growth Hormone Secretagogue

TesamorelinGrowth Hormone-Releasing Hormone Analog